Soliris-to-Enspryng switch safe, effective in NMOSD: Case series

Switching from Soliris (eculizumab) to Enspryng (satralizumab) is a safe and effective approach for neuromyelitis optica spectrum disorder (NMOSD) patients testing positive for antibodies against the AQP4 protein. That’s according to data from five patients in the U.S. who switched treatments due to either preference for route…

Experts publish recommendations for modern NMOSD treatment

An international team of experts has published evidence-based recommendations for how to best treat people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 immunoglobulin G (AQP4-IgG), the most common type of disease-driving antibody. The consensus statements were described in the study “International Delphi…

My Experience With Enspryng Has Been Mostly Positive

What do you do when you’ve run out of choices? That’s where I found myself in May 2020. After living attack-free for 10 years, I was stunned when I found myself dealing with a surprise neuromyelitis optica (NMO) attack. It wasn’t until the end of that summer that I…

NF-kappaB Pathway May Be Useful Therapeutic Target for NMOSD

Astrocytes, star-shaped cells found around nerve cells, make an inflammation driver of neuromyelitis optica spectrum disorder (NMOSD) called interleukin-6 (IL-6) in part by gearing up a chain of reactions involving nuclear factor kappa B, or NF-kappaB, according to a study in rat cells. Researchers also observed that by blocking…